Kuros Biosciences AG
🇨🇭XSWX.KURNSwitzerlandHealthcare
PriceCHF 17.61+0.43 (+2.5%)
Latest anomalies
Neutral 1 detected in the last 120 days
- High: 1
- Medium: 0
- Low: 0
52-week low: the price is trading close to this level
Effective tax rate: a sudden spike above its trailing quarter average
Free with a Finzer account.
Profile
- Healthcare
- Medical Devices
- Switzerland
Identity
- Exchange
- SIX Swiss Exchange . XSWX
- Type
- Stock
- ISIN
- CH0325814116
- CUSIP
- Not reported
Company
- Employees
- 158
- Headquarters
- Schlieren, Switzerland
- Website
- https://kurosbio.com
Market
- Shares outstanding
- 39.7M
- Market cap
- CHF 679.57M
Highlights
- Market cap
- CHF 679.57M
- EPS LTM
- -CHF 0.56
- P/E LTM
- -31.31calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CHF 50.35M+86.61%up year on year
- Net income
- -CHF 20.59M+5.95%up year on year
- Gross margin
- 77.9%+14%up year on year
- Free cash flow
- -CHF 13.75M-18.34%down year on year
Latest news
News is not sourced for this exchange.
Business summary
Kuros Biosciences AG is a company in the healthcare sector, listed on SIX Swiss Exchange (Switzerland) under the ticker KURN. Its market capitalisation is CHF 679.57M, from 39.7M shares outstanding, as of . Across the 249 trading sessions to the shares traded between CHF 16.46 and CHF 34.20, and the last close of CHF 17.61 sits 6% of the way up that range. The company is headquartered in Schlieren, Switzerland, and employs about 158 people.
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.